• 27.05.2002 N 164 " " . " ( " 91500.11.0002-2002...")

    31


    : | « ... | .8 | .9 | .10 | .11 | .12 | .13 | .14 | .15 | .16 | .17 | .18 | .19 | .20 | .21 | .22 | .23 | .24 | .25 | .26 | .27 | .28 | .29 | .30 | .31 | .32 | .33 | .34 |


    58 Glick H.,        Costs and effects of       J. Card.      
       Cook J.,         enalapril therapy in       Fail., 1995;  
       Kinosian B.      patients with symptomatic  1: 371 - 380  
       et al.           heart failure: an economic               
                        analysis of the studies of               
                        left ventricular                         
                        dysfunction (SOLVD)                      
                        treatment trial                          
    +---+-----------------+---------------------------+--------------+
    59 Gregory D.,      Economic impact of beta -  Amer. J. Med.,
       Udelson J.E.,    blockade in heart failure  2001; 110     
       Konstam M.A.                                (suppl. 1):   
                                                   74 - 80       
    +---+-----------------+---------------------------+--------------+
    60 Haque W.A.,      Hemodinamic effects of     J. Amer. Coll.
       Boehmer J.,      supplemental oxygen        Card., 1996;  
       Clemson B.S. et  administration in          27: 353 - 357 
       al.              congestive heart failure                 
    +---+-----------------+---------------------------+--------------+
    61                  Heart Failure: Evaluation  AHCPR         
                        and Care of Patients with  Publication   
                        Left-Ventricular Systolic  No. 94-0612.  
                        Dysfunction. Clinical      June, 1994    
                        Practice Guideline                       
    +---+-----------------+---------------------------+--------------+
    62 Hess O.M.        State of art: current      Europ. Heart  
                        treatment of heart failure J., 2000; 2   
                                                   (Suppl. A):   
                                                   A13 - A16     
    +---+-----------------+---------------------------+--------------+
    63 Hobbs F.D.R.,    European survey of primary Europ. Heart  
       Jones M.I.,      care physician perceptions J., 2000; 21: 
       Allan T.F. et al.on heart failure diagnosis 1877 - 1887   
                        and management (Euro-HF)                 
    +---+-----------------+---------------------------+--------------+
    64 Kannel W.B.,     Epidemiology of heart      Amer. Heart   
       Belanger A.J.    failure                    J., 1991; 121:
                                                   951 - 957     
    +---+-----------------+---------------------------+--------------+
    65 Khand A.U.,      Systematic review of the   Europ. Heart  
       Rankin A.C.,     management of the atrial   J., 2000; 21: 
       Kaye G.C.,       fibrillation in patients   614 - 632     
       Clealand J.G.    with heart failure                       
    +---+-----------------+---------------------------+--------------+
    66 Kleber F.X.      Impact of converting enzymeBrit. Heart   
                        inhibition on progression  J., 1992; 67: 
                        of chronic heart failure:  289 - 296     
                        results of the Munich Mild               
                        Heart Failure Trial                      
    +---+-----------------+---------------------------+--------------+
    67 Kleber F.X.      Socioeconomic aspects of   Amer.         
                        ACE inhibition in the      J. Hypertens.,
                        secondary prevention in    1994; 7:      
                        cardiovascular diseases    112S - 116S   
    +---+-----------------+---------------------------+--------------+
    68 Konstam M.A. et  Heart failure: evaluation  Clinical      
       al. (eds)        and care of patients with  practice      
                        left-ventricular systolic  guidelines.   
                        dysfunction                N 11. Rock-   
                                                   ville, 1994   
    +---+-----------------+---------------------------+--------------+
    69 Lenihan D.J.,    Mechanism, diagnosis and   Amer. Heart   
       Gerson M.C.,     treatment of diastolic     J., 1995; 130:
       Hoit B.D.,       heart failure              153 - 166     
       Walsh R.A.                                                
    +---+-----------------+---------------------------+--------------+
    70 Levy P.,         A cost-minimization of     Cardiovascular
       Lechat Ph.,      heart failure therapy with Drugs Therapy,
       Leizorovicz A.,  bisoprilol in the French   1998; 12:     
       Levy E.          setting: an analysis from  301 - 305     
                        CIBIS trial data                         
    +---+-----------------+---------------------------+--------------+
    71 Levy S.,         Atrial fibrillation:       Euop. Heart   
       Breithardt G.,   current knowledge and      J., 1998; 19: 
       Campbell R.W.    recommendation for         1294 - 1320   
       et al.           management                               
    +---+-----------------+---------------------------+--------------+
    72 Massie B.M.,     Evolving trends in the     Amer. Heart   
       Shah N.B.        epidemiologic factors of   J., 1997; 133:
                        heart failure: Relations   703 - 712     
                        for preventive strategies                
                        and comprehensive disease                
                        management                               
    +---+-----------------+---------------------------+--------------+
    73 The MERIT-HF     Metoprolol CR/XL randomizedLancet, 1999; 
       Study Group      intervention trial in      353:          
                        congestive heart failure   2001 - 2007   
                        (MERIT-HF)                               
    +---+-----------------+---------------------------+--------------+
    74 McMurray J.,     The pharmacoeconomics of   Pharmacoecono-
       Davie A.         ACE inhibitors in chronic  mics, 1996; 9:
                        heart failure              188 - 197     
    +---+-----------------+---------------------------+--------------+
    75 McMurray J.J.,   Clinical epidemiology of   Europ. Heart  
       Petrie M.C.,     heart failure: public and  J., 1998; 19  
       Murdack D.R.,    private health burden      (Suppl. P):   
       Davie A.P.                                  9 - 16        
    +---+-----------------+---------------------------+--------------+
    76 Nishimura R.,    Evaluation of diastolic    J.Amer. Coll. 
       Tajik J.         filling of left ventricule Card., 1997;  
                        in health and disease:     30: 8 - 18    
                        doppler echocardiography is              
                        the clinician's Rosetta                  
                        Stone                                    
    +---+-----------------+---------------------------+--------------+
    77 Opie L.H.        Angiotensin Converting     New York, 1999
                        Enzyme Inhibitors. 3th                   
                        edition                                  
    +---+-----------------+---------------------------+--------------+
    78 Packer M.,       Consensus recommendations  Amer. J.      
       Cohn J.N.        for the management of      Cardiol.,     
       (eds)            chronic heart failure      1999; 83 (2A):
                                                   1A - 38A      
    +---+-----------------+---------------------------+--------------+
    79 Packer M.,       Withdeawal of digoxin from New Engl. J.  
       Gheorghiade M.,  patients with chronic heartMed., 1993;   
       Young J.B.       failure treated with       329: 1 - 7    
       et al.           angiotensin-converting                   
                        enzyme inhibitors: RADIANCE              
                        study                                    
    +---+-----------------+---------------------------+--------------+
    80 Packer M.,       Comparative effects of low Circulation,  
       Pool-Wilson P.A.,and high doses of the      1999; 100:    
       Armstrong P.W.   angiotensin-converting     2312 - 2318   
       et al.           enzyme inhibitors,                       
                        lisinopril, on morbidity                 
                        and mortality in chronic                 
                        heart failure                            
    +---+-----------------+---------------------------+--------------+
    81 Pfeffer M.A.,    Effects of captopril on    New Engl. J.  
       Braunwald E.,    mortality and morbidity in Med., 1992;   
       Moye L.A. et al. patients with left         327: 669 - 677
                        ventricular dysfunction                  
                        after myocardial                         
                        infarction: Results of the               
                        Survival And Ventricular                 
                        Enlargement trial                        
    +---+-----------------+---------------------------+--------------+
    82 Philbin E.F.,    Differences between        Amer. Heart   
       Jenkins P.L.     patients with heart failureJ., 2000; 139:
                        treated by cardiologists,  491 - 496     
                        internists, family                       
                        physicians and other                     
                        physicians: analysis of a                
                        large, statewide database                
    +---+-----------------+---------------------------+--------------+
    83 Pitt .,         Randomized trial of        Lancet, 1997; 
       Segal R.,        losartan versus captopril  349: 747 - 752
       Martinez F.A.    in patients over 65 with                 
       et al.           heart failure (Evaluation                
                        of Losartan In The Elderly               
                        study, ELITE)                            
    +---+-----------------+---------------------------+--------------+
    84 Pitt .,         The effect of              New Engl. J.  
       Zannad F.,       spironolactone on morbidityMed., 1999;   
       Remme W.J. et al.and mortality in patients  341: 709 - 717
                        with severe heart failure.               
                        Randomized Aldactone                     
                        Evaluation Study                         
                        Investigators                            
    +---+-----------------+---------------------------+--------------+
    85 Remes J.,        Validity of clinical       Europ. Heart  
       Miettinen H.,    diagnosis of heart failure J., 1991; 12: 
       Reunanen A.,     in primary health care     315 - 321     
       Pyorala K.                                                
    +---+-----------------+---------------------------+--------------+
    86 Richardson M.,   Update of recent clinical  Europ. J.     
       Cockburn N.,     trials in heart failure andHeart Failure,
       Cleland J.G.F.   myocardial infarction      1999; 1 (1):  
                                                   109 - 115     
    +---+-----------------+---------------------------+--------------+
    87 Rogers W.J.,     Quality of life among 5025 J. Amer. Coll.
       Johnstone D.E.,  patients with left         Card., 1994;  
       Yusuf S.,        ventricular dysfunction    23: 393 - 400 
       Weiner D.H.      randomized between placebo               
       et al.           and enalapril: studies of                
                        left ventricular                         
                        dysfunction                              
    +---+-----------------+---------------------------+--------------+
    88 Ryden L.         A review of evidence of    Europ. Heart  
                        benefits from ACE          J., 1999; 1   
                        inhibitores in heart       (suppl. Q):   
                        failure compared with AT1 -Q3 - Q6       
                        receptor blockers and other              
                        therapies                                
    +---+-----------------+---------------------------+--------------+
    89 Sculpher M.J.,   Low doses vs high doses of Europ. J.     
       Poole L.,        the angiotensin -          Heart Fail.,  
       Cleland J. et al.converting enzyme          2000; 2:      
                        inhibitor lisinopril in    447 - 454     
                        chronic heart failure: a                 
                        cost-effectiveness                       
                        analysis based on the                    
                        Assessment of Treatment                  
                        with Lisinipril And                      
                        Survival (ATLAS) study                   
    +---+-----------------+---------------------------+--------------+
    90 Senni M.,        Use of echocardiography in J. Amer. Coll.
       Rodeheffer R.J., the management of          Card., 1999;  
       Tribouilloy C.M. congestive heart failure in33: 164 - 170 
       et al.           the community                            
    +---+-----------------+---------------------------+--------------+
    91 Setaro J.F.,     Long-term outcome in       Amer. J.      
       Saufer R.,       patients with congestive   Cardiol.,     
       Remetz M.S.,     heart failure and intact   1992; 69:     
       Parlmutter R.A., systolic left ventricular  1212 - 1216   
       Zaret B.L.       performance                              
    +---+-----------------+---------------------------+--------------+
    92 Singh S.N.,      Amiodaron in patients with New Engl. J.  
       Fletcher R.D.,   congestive heart failure   Med., 1995;   
       Fisher S.G. et   and asymptomic ventricular 333: 77 - 82  
       al.              arrhythmia                               
    +---+-----------------+---------------------------+--------------+
    93 SOLVD (Studies ofEffect of enalapril on     New Engl. J.  
       Left Ventricular survival in patients with  Med., 1991;   
       Dysfunction)     reduced left ventricular   325: 293 - 302
       Investigators    ejection fractions and                   
                        congestive heart failure                 
    +---+-----------------+---------------------------+--------------+
    94 SOLVD (Studies ofEffect of enalapril on     New Engl. J.  
       Left Ventricular mortality and the          Med., 1992;   
       Dysfunction)     development of heart       327: 685 - 691
       Investigators    failure in asymptomic                    
                        patients with reduced left               
                        ventricular ejection                     
                        fractions                                
    +---+-----------------+---------------------------+--------------+
    95 Squire I..,     Differing early blood      J. Hypertens.,
       MacFayden R.J.,  pressure and renin -       1995; 27:     
       Reid J.L. et al. angiotensin system         657 - 666     
                        responses to the first dose              
                        of angiotensin converting                
                        enzyme inhibition in                     
                        congestive heart failure                 
    +---+-----------------+---------------------------+--------------+
    96 Strope K.T.,     Health care costs of       Pharmacoecono-
       Forthofer M.M.,  patients with heart failuremics, 2000;   
       Brater D.C.,     treated with torasemide or 17: 429 - 440 
       Murrey M.D.      furosemide                               
    +---+-----------------+---------------------------+--------------+
    97                  Task Force on Heart FailureEurop. Heart  
                        of the European Society of J., 1995; 16: 
                        Cardiology. Guidelines for 741 - 751     
                        the diagnosis of heart                   
                        failure                                  
    +---+-----------------+---------------------------+--------------+
    98                  Task Force of Working GroupEurop. Heart  
                        on Heart Failure of the    J., 1997; 18: 
                        European Society of        736 - 753     
                        Cardiology. The treatment                
                        of heart failure                         
    +---+-----------------+---------------------------+--------------+
    99 Tendera M.       Ageing and heart failure:  Europ. Heart  
                        the place of ACE inhibitorsJ., 2000; Vol.
                        in heart failure with      2 (Suppl. 1): 
                        preserved systolic functionP. 18 - 114   
    +---+-----------------+---------------------------+--------------+
    100Thackray S.,     Clinical trials update:    Europ. J.     
       Witte K.,        OPTIME-CHF, PRAISE-2,      Heart Fail.,  
       Clark A.I.,      ALL-HAT                    2000; 2:      
       Clealand J.G.                               209 - 212     
    +---+-----------------+---------------------------+--------------+
    101Uretsky B.F.,    Randomized study assesing  J. Amer. Coll.
       Young J.B.,      the effect of digoxin      Card., 1993;  
       Shahidi F.E. et  withdrawal in patients with22: 955 - 962 
       al.              mild to moderate chronic                 
                        congestive heart failure:                
                        results of the PROVED trial              
    +---+-----------------+---------------------------+--------------+
    102Vandenburg M.J., Digoxin pharmacokinetics   J. Clin.      
       Stephens J.D.,   and perindopril in heart   Pharmacol.,   
       Resplandy G. et  failure patients           1993; 33:     
       al.                                         146 - 149     
    +---+-----------------+---------------------------+--------------+
    103Vasan R.S.,      Congestive heart failure inJ. Amer. Coll.
       Larson M.G.,     subjects with normal versusCard., 1999;  
       Benjamin E.J.,   reduced left ventricular   33 (7):       
       Evans J.C.,      ejection fraction:         1948 - 1955   
       Reiss C.K,       Prevalence and mortality in              
       Levy D.          a population-based cohort                
    +---+-----------------+---------------------------+--------------+
    104Vitovec J.,      First-dose hypotension     Europ. J.     
       Spinar J.        after angiotensin -        Heart Fail.,  
                        converting enzyme (ACE)    2000; 2 (3):  
                        inhibitors in chronic heart299 - 304     

    : | « ... | .8 | .9 | .10 | .11 | .12 | .13 | .14 | .15 | .16 | .17 | .18 | .19 | .20 | .21 | .22 | .23 | .24 | .25 | .26 | .27 | .28 | .29 | .30 | .31 | .32 | .33 | .34 |


 

  • @Mail.ru